All In Biotech

NDA 050781 · Orapharma

Arestin

Minocycline Hydrochloride · Dental

Last checked: Nov 19, 2026Latest source record: May 24, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Feb 16, 2001

Approved uses

1

Original approval plus efficacy supplements

Registered trials

291

55 Phase 3, 18 recruiting

FAERS reports

5,103

4,179 serious, 1,656 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 31, 2024.

INDICATIONS AND USE ARESTIN is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN may be used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing.

Mechanism: Mechanism of Action The mechanism of action of ARESTIN as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 16, 2001 Original approval · Type 3 - New Dosage Form LabelReview
1 products under this application
  • ARESTIN · MINOCYCLINE HYDROCHLORIDE EQ 1MG BASE · POWDER, EXTENDED RELEASE, DENTAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Minocycline" as an intervention, any sponsor and status, largest first.

All 291 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,272
  • off label use1,161
  • drug intolerance966
  • pain929
  • rheumatoid arthritis895
  • rash793
  • nausea791
  • arthralgia775
  • drug hypersensitivity753
  • joint swelling733
  • fatigue699
  • c-reactive protein increased680

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200432
200538
200644
200799
200873
200957
201043
201155
2012101
201345
2014151
2015137
2016202
2017230
2018250
2019303
2020300
2021256
2022404
2023422
2024714
2025802
2026345

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Arestin (Minocycline HCl Microspheres)

2024 spending

$5.1M

Beneficiaries

1,027

1,166 claims

Per beneficiary

$4,999

$102.76 per unit

View as table
YearSpending
2020$4,870,758
2021$5,500,961
2022$5,467,459
2023$5,814,308
2024$5,134,006

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 690 on PubMed

Sponsor: Orapharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.